Skip to main content

Newsroom

 About Hepion
Recent News
 Contact Us

Recent Press Releases

View all Press Releases

Hepion in the Media

View all Media Placements

NASH on the Cusp: An Emerging Market Opportunity [BioSpace]

https://www.biospace.com/article/nash-on-the-cusp-an-emerging-market-opportunity-/

As it awaits key readout, Hepion boosts confidence in NASH drug hopeful via shorter study [Endpoints]

https://endpts.com/as-it-awaits-key-readout-hepion-boosts-confidence-in-nash-drug-hopeful-via-shorter-study/

Fatty Liver, NASH, Cirrohosis – Can They Be Stopped??? [BioTech Nation]

https://www.biotechnation.com/episodes/fatty-liver-nash-cirrohosis-can-they-be-stopped

GEN2 NASH Therapies Near the Finish Line [Biospace]

https://www.biospace.com/article/gen2-nash-therapies-near-the-finish-line-/

What I Learned As CEO The First Time Around [Life Science Leader]

https://www.lifescienceleader.com/doc/what-i-learned-as-ceo-the-first-time-around-0001

Hepion Pharmaceuticals’ Lead Therapy, Rencofilstat [Oncology Tube]

https://oncologytube.com/v/41256#gsc.tab=0

Hepion Pharma’s Liver Cancer Candidate Secures Orphan Drug Tag [Markets Insider]

https://markets.businessinsider.com/news/stocks/the-daily-biotech-pulse-thumbs-down-for-acadia-s-pimavanserin-pfizer-buys-stake-in-valneva-astrazeneca---ionis-eplontersen-aces-rare-disease-trial-1031540289

FDA grants orphan drug designation to rencofilstat for hepatocellular carcinoma [Healio]

https://www.healio.com/news/hematology-oncology/20220620/fda-grants-orphan-drug-designation-to-rencofilstat-for-hepatocellular-carcinoma

FDA Grants Orphan Drug Designations to VBI, Hepion Cancer Drugs [BioSpace]

https://www.biospace.com/article/fda-approves-orphan-drug-designations-for-vbi-hepion-cancer-drugs/

Tackling Liver Disease with a Multimodal Cyclophilin Inhibitor [Pharma’s Almanac]

https://www.pharmasalmanac.com/articles/tackling-liver-disease-with-a-multimodal-cyclophilin-inhibitor?hs_preview=FMelfVXS-74910818711
Media Placements

Can Hepion Pharmaceuticals Develop the First Treatment Approved For NASH? With Robert Foster, Pharm D, PhD [Biotech IQ]

JTNDYSUyMGhyZWYlM0QlMjJodHRwcyUzQSUyRiUyRnRoZWJpb3RlY2hpcXBvZGNhc3QuY29tJTJGY2FuLWhlcGlvbi1waGFybWFjZXV0aWNhbHMtZGV2ZWxvcC10aGUtZmlyc3QtdHJlYXRtZW50LWFwcHJvdmVkLWZvci1uYXNoLXdpdGgtcm9iZXJ0LWZvc3Rlci1waGFybS1kLXBoZCUyMiUyMHRhcmdldCUzRCUyMl9ibGFuayUyMiUyMHJlbCUzRCUyMm5vb3BlbmVyJTIyJTNFJTNDaW1nJTIwc3JjJTNEJTIyaHR0cHMlM0ElMkYlMkZ0aGViaW90ZWNoaXFwb2RjYXN0LmNvbSUyRndwLWNvbnRlbnQlMkZ1cGxvYWRzJTJGMjAyMiUyRjA0JTJGR3JhcGhpY3MtRWdvQmFpdC1CVEktNDctUm9iZXJ0LUZvc3Rlci5wbmclMjIlMjAlMkYlM0UlM0MlMkZhJTNF
Hepion
May 4, 2022

Q&A With Robert Foster, CEO of Hepion Pharmaceuticals [Pharm Exec]

https://www.pharmexec.com/view/q-a-with-robert-foster-ceo-of-hepion-pharmaceuticals

Hepion Striving to Repeat History by Developing its Second FDA-Approved Drug [via Benzinga]

https://www.benzinga.com/general/biotech/21/03/20282078/hepion-striving-to-repeat-history-by-developing-its-second-fda-approved-drug

Breakthrough lupus drug ‘home grown’ by Edmonton doctor approved by FDA for use [via Global News]

https://globalnews.ca/news/7670080/lupkynis-voclosporin-edmonton-drug-approved-lupus/

‘Huge potential opportunity’ for Edmonton Pharmaceutical Industry as FDA Approves Aurinia Lupus Drug [Taproot Edmonton]

https://edmonton.taproot.news/news/2021/02/03/huge-potential-opportunity-for-edmonton-pharmaceutical-industry-as-fda-approves-aurinias-lupus-drug

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH [BioTuesdays]

https://hepionpharma.com/wp-content/uploads/2020/11/BioTuesdays-November-2020.pdf

Amidst a global pandemic, two biotech companies offer innovative solutions [BioTuesdays]

https://biotuesdays.com/2020/03/31/amidst-a-global-pandemic-two-biotech-companies-offer-innovative-solutions/

Breakthrough lupus drug discovered in Edmonton passes final testing phase [Global News]

https://globalnews.ca/news/6273515/lupus-drug-edmonton-discovery/

Research institute launched out of U of A attracts $25 million in investments [Edmonton Journal]

https://edmontonjournal.com/business/local-business/research-institute-launched-out-of-u-of-a-attracts-25-million-in-investments

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH [BioTuesdays]

https://www.biotuesdays.com/features/2019/7/30/hepion-pharmaceuticals-ceo-robert-foster-discusses-crv431s-potential-in-nash

Robert Foster swinging for the fence again with Hepion Pharma [BioTuesdays]

http://www.biotuesdays.com/features/2018/11/7/robert-foster-swinging-for-the-fence-again-with-contravir-pharma
Industry News

BIO Launches DrugCostFacts.org

What is biotechnology? At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and…
Hepion
July 26, 2017

An Update on Hepatitis B Therapies [Drug Discovery World]

http://www.ddw-online.com/fall-2016/p315872-an-update-on-hepatitis-b-therapies.html

Dr. Robert Foster, Chief Scientific Officer of Hepion, invited to join the Faculty of Pharmacy & Pharmaceutical Sciences at the University of Alberta as an Honorary Professor

https://hepionpharma.com/wp-content/uploads/2016/07/RTF-Professorship.pdf

The Rise of the CFO Strategist: Balancing Numbers and Know-how [Via PharmaExec]

http://www.pharmexec.com/rise-cfo-strategist-balancing-numbers-and-know-how

Hepion Hopes To Establish Backbone For Hepatitis B Combo Therapy [via Scrip]

https://scrip.pharmamedtechbi.com/SC096933/Hepion-Hopes-To-Establish-Backbone-For-Hepatitis-B-Combo-Therapy

Should Gilead Sciences Feel Threatened By Hepion’s Hepatitis B Drug? [via Bidness Etc]

http://www.bidnessetc.com/66362-gilead-sciences-feel-threatened-contravirs-hepatitis-b-drug/

Hepatitis Quest Moves From C to B Under Ex-Gilead Leaders [via Bloomberg Business]

http://www.bloomberg.com/news/articles/2015-02-04/hepatitis-quest-moves-from-c-to-b-under-former-gilead-executives

Hepion Obtains HBV Candidate, Investment from Chimerix

http://www.biocentury.com/dailynews/company/2014-12-18/contravir-obtains-hbv-candidate-investment-from-chimerix

Media Contact